Current Report Filing (8-k)
July 07 2017 - 4:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): July 7, 2017
Inotek Pharmaceuticals Corporation
(Exact name of registrant as specified in its charter)
|
|
|
|
|
DELAWARE
|
|
001-36829
|
|
04-3475813
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
91 Hartwell Avenue
Lexington, MA
|
|
02421
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code (781) 676-2100
Not Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the
Securities Exchange Act of 1934.
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
On July 7, 2017, Inotek Pharmaceuticals Corporation (the
Company) issued a press release announcing the top-line results of the Phase 2 fixed-dose combination trial of
trabodenoson
and
latanoprost
for the treatment of glaucoma. The Company also announced that it is reviewing its
strategic alternatives and that it retained Perella Weinberg Partners to assist in the process. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press release issued by Inotek Pharmaceuticals Corporation on July 7, 2017, furnished herewith.
|
* * *
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
Date: July 7, 2017
|
|
|
|
INOTEK PHARMACEUTICALS CORPORATION
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Dale Ritter
|
|
|
|
|
|
|
Dale Ritter
|
|
|
|
|
|
|
Vice President Finance
|
EXHIBIT INDEX
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press release issued by Inotek Pharmaceuticals Corporation on July 7, 2017, furnished herewith.
|
INOTEK PHARMACEUTICALS CORP (NASDAQ:ITEK)
Historical Stock Chart
From Mar 2024 to Apr 2024
INOTEK PHARMACEUTICALS CORP (NASDAQ:ITEK)
Historical Stock Chart
From Apr 2023 to Apr 2024